Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodium mitochondrial electron transport chain (mtETC) is a vital metabolic pathway in malaria-causing parasites, distinct from its human counterpart in both structure and primary function. While human mitochondria primarily use the ETC for ATP production via oxidative phosphorylation, blood-stage Plasmodium parasites rely on it mainly as an electron sink for dihydroorotate dehydrogenase (DHODH), an essential enzyme in the de novo pyrimidine biosynthesis pathway (Painter et al., 2007, Nature). Because Plasmodium cannot salvage preformed pyrimidines, inhibition of the mtETC—specifically the cytochrome bc1 complex (Complex III)—effectively halts DNA and RNA synthesis, leading to parasite death (Fry & Pudney, 1992, Biochem Pharmacol). The chain also includes a unique single-subunit NADH dehydrogenase (NDH2) that is absent in humans, making it an attractive target for selective toxicity (Fisher et al., 2007, J Biol Chem). This pathway is the target of the clinical antimalarial atovaquone and several next-generation candidates like ELQ-300. However, the high rate of resistance mutations in the mitochondrial-encoded cytochrome b gene remains a significant therapeutic challenge (Kessl et al., 2007, J Biol Chem).
Inhibition of the cytochrome bc1 complex (Complex III) prevents the turnover of ubiquinol to ubiquinone, which is a necessary cofactor for dihydroorotate dehydrogenase (DHODH), thereby halting de novo pyrimidine biosynthesis and disrupting the mitochondrial membrane potential (Mather et al., 2007, Molecular and Biochemical Parasitology; Painter et al., 2007, Nature).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium mitochondrial electron transport chain (mtETC) (mtETC).